Upgrade to SI Premium - Free Trial

Revance Therapeutic (RVNC) PT Raised to $32 at Goldman Sachs

February 20, 2020 6:09 AM
Goldman Sachs analyst Terence Flynn ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst PT Change

Next Articles